Nmedis Sp. z o.o.

Rzeszow 16 trials 8 recruiting

16 Registered trials

8 Currently recruiting

Organisation

Nmedis Sp. z o.o.

Location

Rzeszow, Poland

Identifier

ORG-100050437

Address

Ul. Kujawska 5, 35-323, Poland

Departments

1907
4103
6001
N/A
NA
Nmedis

Clinical trials at this site (16)

Search interface

A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending

2025-524322-18-00 Non-active Secondary Progressive Multiple Sclerosis (SP 5
A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Recruiting

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2026-06-11
An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518006-40-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-13
Concentration of ofatumumab in the breast milk of lactating women with relapsing forms of multiple sclerosis Recruiting

2023-505283-11-00 Relapsing forms of Multiple Sclerosis (RMS) 6 2024-12-10
Study of an On-Body Injection System for Home Use of Ocrelizumab in People with Multiple Sclerosis Recruiting

2025-523726-40-00 Multiple Sclerosis 5 2026-06-24
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has… Recruiting

2025-521636-10-00 Progressive Forms of Multiple Sclerosis (PMS) 4 2026-02-04
A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting

2025-522683-32-00 Early-Stage Parkinson’s Disease (PD) 5 2026-01-15
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patient… Recruiting

2023-510026-32-00 Generalized Myasthenia Gravis 5 2025-06-11
A Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Participants with Multiple Sclerosis Ended

2024-517980-22-00 Multiple Sclerosis (MS) 4 2025-12-10
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509345-12-00 Multiple Sclerosis 5 2022-06-22
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease Ended

2023-507132-21-00 Early Parkinson's disease 10 2021-05-11
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc… Ended

2022-502611-10-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-11-24
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc… Ended

2023-506515-18-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-10-23
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended

2023-506467-34-00 Relapsing Multiple Sclerosis (MS) 5 2020-10-20
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adult… Ended

2022-502552-31-00 Relapsing Forms of Multiple Sclerosis 4 2023-10-03